Literature DB >> 15452451

Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics.

E de Vries1, F I Bray, A M M Eggermont, J W W Coebergh.   

Abstract

Cutaneous malignant melanoma has been characterized by rapid and steady increases in incidence and mortality in white populations. Some reports mentioned declining trends in the mean thickness of these tumours, but other studies suggested a stable incidence of thick melanomas. The aim of this study was to describe the stage distribution of melanomas across Europe, with particular reference to temporal trends. Twenty-three cancer registries provided data sets containing information on stage and histology, 21 of which were used for a general description and nine for trends analyses. Despite a preponderance of missing data, interesting patterns emerged: a less favourable stage distribution in populations with relatively low incidence, but high case-fatality rates, and a favourable trend in stage and histology distribution over time, including a shift from later to earlier stages in recent years. Early detection campaigns raising awareness for thin lesions can potentially improve melanoma survival rates. Monitoring of stage-specific trends in melanoma incidence can assess the impact of such interventions. This paper demonstrates the potential utility of high-quality, timely cancer registry data in pursuing such public health objectives and addresses the need for more complete information on diagnostic features of melanoma patients. This will allow more informative evaluations of preventive strategies.

Entities:  

Mesh:

Year:  2004        PMID: 15452451     DOI: 10.1097/00008469-200410000-00006

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  7 in total

1.  p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome.

Authors:  Giovanni Ponti; Gabriele Luppi; Lorena Losi; Anna Maria Cesinaro; Giuliana Sartori; Antonio Maiorana; Giovanni Pellacani; Caterina Longo; Elisa Boni; Patrizia Pepe; Alberto Giannetti; Stefania Seidenari; Maria Teresa Landi
Journal:  Int J Dermatol       Date:  2011-06-15       Impact factor: 2.736

2.  More people die from thin melanomas (⩽1 mm) than from thick melanomas (>4 mm) in Queensland, Australia.

Authors:  David C Whiteman; Peter D Baade; Catherine M Olsen
Journal:  J Invest Dermatol       Date:  2014-10-20       Impact factor: 8.551

Review 3.  The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.

Authors:  Florentia Dimitriou; Regina Krattinger; Egle Ramelyte; Marjam J Barysch; Sara Micaletto; Reinhard Dummer; Simone M Goldinger
Journal:  Curr Oncol Rep       Date:  2018-09-24       Impact factor: 5.075

4.  Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993-2003.

Authors:  A Downing; J A Newton-Bishop; D Forman
Journal:  Br J Cancer       Date:  2006-06-06       Impact factor: 7.640

Review 5.  Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.

Authors:  Fernanda Costa Svedman; Demetris Pillas; Aliki Taylor; Moninder Kaur; Ragnar Linder; Johan Hansson
Journal:  Clin Epidemiol       Date:  2016-05-26       Impact factor: 4.790

Review 6.  Are inequalities in cancer diagnosis through emergency presentation narrowing, widening or remaining unchanged? Longitudinal analysis of English population-based data 2006-2013.

Authors:  Annie Herbert; Gary A Abel; Sam Winters; Sean McPhail; Lucy Elliss-Brookes; Georgios Lyratzopoulos
Journal:  J Epidemiol Community Health       Date:  2018-11-08       Impact factor: 3.710

7.  Stage-specific incidence trends of melanoma in an English region, 1996-2015: longitudinal analyses of population-based data.

Authors:  Annie Herbert; Minjoung M Koo; Matthew E Barclay; David C Greenberg; Gary A Abel; Nick J Levell; Georgios Lyratzopoulos
Journal:  Melanoma Res       Date:  2020-06       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.